PRSS3 and cancer: Kaplan–Meier (K-M) analysis revealed that PRSS3-V2Low was a favorable factor for the overall survival of HCC patients based on cancer stage (Figure 6C) and grade (Figure 6D), in which PRSS3-V2Low patient groups with low-grade tumors showed significantly favorable outcomes (P=0.011).